Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia

Blood Cancer J. 2017 Feb 3;7(2):e521. doi: 10.1038/bcj.2017.4.

Authors

Z Chen¹, L J Medeiros¹, H M Kantajian², L Zheng¹, Z Gong¹, K P Patel¹, H Xiong³, W Wang¹, J E Cortes², S Hu¹

Affiliations

¹ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Hematology, Shanghai Xuhui Central Hospital, Shanghai, China.

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use
Blast Crisis / mortality
Blast Crisis / pathology
Blast Crisis / therapy*
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Male
Middle Aged
Prognosis
Protein Kinase Inhibitors / therapeutic use
Transcriptome / drug effects*
Transplantation, Homologous
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Protein Kinase Inhibitors